Other
Unrealized gains (losses) on available-for-sale securities
Year-over-year, this metric declined by 847.1%, from $1.70M to -$12.70M. Over 3 years (FY 2021 to FY 2025), Unrealized gains (losses) on available-for-sale securities shows an upward trend with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2018
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase reflects rising market values of the company's investment portfolio, while a decrease reflects market volatility or impairment.
Detailed definition
Unrealized changes in the fair value of investment securities classified as available-for-sale. These gains or losses ar...
Peer comparison
Standard for companies holding significant portfolios of marketable securities.
Metric ID:
other_other_comprehensive_income_loss_available_for_sale_e590c8Historical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$300.00K | -$300.00K | -$2.10M | -$7.60M | -$2.90M | -$1.80M | $4.00M | $700.00K | $800.00K | $7.00M | -$3.20M | -$900.00K | $9.10M | -$5.10M | $1.70M | $2.70M | -$900.00K | $0.00 | -$12.70M |
| QoQ Change | — | +0.0% | -600.0% | -261.9% | +61.8% | +37.9% | +322.2% | -82.5% | +14.3% | +775.0% | -145.7% | +71.9% | >999% | -156.0% | +133.3% | +58.8% | -133.3% | +100.0% | — |
| YoY Change | — | — | — | — | -866.7% | -500.0% | +152.6% | +124.1% | +144.4% | — | -180.0% | -228.6% | >999% | -172.9% | +153.1% | +400.0% | -109.9% | +100.0% | -847.1% |
Range-$12.70M – $9.10M
CAGR+129.9%
Avg YoY Growth-56.7%
Median YoY Growth-4.9%
Unrealized gains (losses) on available-for-sale securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's unrealized gains (losses) on available-for-sale securities?
- Neurocrine Biosciences (NBIX) reported unrealized gains (losses) on available-for-sale securities of -$12.70M in Q1 2026.
- How has Neurocrine Biosciences's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Neurocrine Biosciences's unrealized gains (losses) on available-for-sale securities decreased by 847.1% year-over-year, from $1.70M to -$12.70M.
- What is the long-term trend for Neurocrine Biosciences's unrealized gains (losses) on available-for-sale securities?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's unrealized gains (losses) on available-for-sale securities has grown at a 0.0% compound annual growth rate (CAGR), from -$3.50M to $3.50M.
- What does unrealized gains (losses) on available-for-sale securities mean?
- Changes in the market value of investment holdings that haven't been sold yet.